The risk for major adverse cardiovascular events decreased with tirzepatide vs. liraglutide and semaglutide in patients with ...

A post hoc analysis of the SUMMIT trial, published in JACC, reveals that baseline body mass index (BMI) and fat distribution ...

Once-weekly tirzepatide conferred a similar cardiovascular risk as once-weekly dulaglutide in adults with type 2 diabetes and ...

The updated standard replaces three previous guidelines and reflects the latest thinking on tackling obesity through the ...

In patients with type 2 diabetes and CVD, the GIP/GLP-1 agonist was as good as the older drug, and possibly better in some ...

Digital health company Noom has started offering lower doses of GLP-1 agonist semaglutide, the active ingredient in Novo Nordisk's weight-loss drug Wegovy, at a knock-down price. The 'microdose' ...

Doctors at ZAVA warned that these summer staples can cause your blood sugar levels to crash and dehydrate you. This effect ...

Novo Nordisk underestimated the impact of competition from personalized compounded drugs when providing sales estimates for ...

Topline results from the SURPASS-CVOT trial reveal that once-weekly tirzepatide (Mounjaro) has a cardiovascular risk profile ...

SURPASS-CVOT evaluated the efficacy and safety of tirzepatide compared with dulaglutide in adults with T2D and a confirmed ASCVD.

Dear E.M.: Obstructive sleep apnea is when a person stops breathing during sleep due to obstruction of their airway. Some ...

Patients coming off weight loss jabs need support and advice for at least a year to ensure lasting benefit from the drugs, the UK’s medicine watchdog has said. An estimated four in five patients who ...